KD Logo

10x Genomics Inc’s latest rating changes from various analysts

10x Genomics Inc’s filing revealed that its Chief Executive Officer Saxonov Serge unloaded Company’s shares for reported $0.21 million on Mar 04 ’24. In the deal valued at $44.00 per share,4,660 shares were sold. As a result of this transaction, Saxonov Serge now holds 842,900 shares worth roughly $24.68 million.

Then, Saxonov Serge sold 2,821 shares, generating $130,737 in total proceeds. Upon selling the shares at $46.34, the Chief Executive Officer now owns 847,560 shares.

Before that, Hindson Benjamin J. sold 2,613 shares. 10x Genomics Inc shares valued at $121,098 were divested by the insider at a price of $46.34 per share. As a result of the transaction, Hindson Benjamin J. now holds 283,059 shares, worth roughly $8.29 million.

Guggenheim initiated its 10x Genomics Inc [TXG] rating to a Buy in a research note published on December 14, 2023; the price target was $60. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. BofA Securities also remained covering TXG and has increased its forecast on December 12, 2023 with a “Neutral” recommendation from previously “an Underperform” rating.

Price Performance Review of TXG

On Tuesday, 10x Genomics Inc [NASDAQ:TXG] saw its stock jump 3.10% to $29.28. Over the last five days, the stock has gained 6.16%. 10x Genomics Inc shares have fallen nearly -47.68% since the year began. Nevertheless, the stocks have fallen -44.15% over the past one year. While a 52-week high of $63.57 was reached on 01/02/24, a 52-week low of $26.30 was recorded on 04/25/24. SMA at 50 days reached $37.13, while 200 days put it at $44.48. A total of 2.57 million shares were traded, compared to the trading of 1.46 million shares in the previous session.

Levels Of Support And Resistance For TXG Stock

The 24-hour chart illustrates a support level at 27.96, which if violated will result in even more drops to 26.63. On the upside, there is a resistance level at 29.99. A further resistance level may holdings at 30.69. The Relative Strength Index (RSI) on the 14-day chart is 35.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.27, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.67%. Stochastics %K at 20.43% indicates the stock is a holding.

The most recent change occurred on May 10, 2023 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.

Most Popular

[the_ad id="945"]